» Articles » PMID: 11134300

Identification of a Novel Element Involved in Regulation of the Lytic Switch BZLF1 Gene Promoter of Epstein-Barr Virus

Overview
Journal J Virol
Date 2001 Jan 3
PMID 11134300
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Epstein-Barr virus (EBV) is a human herpesvirus capable of establishing a latent state in B lymphocytes. EBV's BZLF1 gene product plays a central role in regulating the switch from latency to productive infection. Here, we identify a sequence element, 5'-CAGGTA-3', called ZV, located at nucleotides -17 to -12 relative to the transcription initiation site of the BZLF1 promoter. ZV sequence-specifically binds a cellular nuclear factor(s), ZVR. ZVR DNA-binding activity was present in the EBV-negative B-lymphocytic cell line DG75, the EBV-positive B-lymphocytic cell lines GG68 and 721, the cervical cell line C33A, and the kidney cell line CV-1 but not in the breast carcinoma cell line MCF-7. Mutations in ZV that relieve binding of ZVR lead to a two- to fourfold increase in basal expression of the BZLF1 promoter in DG75, C33A, and CV-1 cells. The same mutants exhibited a 40- to 180-fold increase in tetradecanoyl phorbol acetate-ionomycin-induced expression in DG75 cells and a 22-fold increase in C33A cells. Thus, ZVR functions as a regulator of the BZLF1 promoter, repressing transcription when bound to the ZV site in the absence of inducers. No differences in basal or induced transcription between wild-type and ZV mutant BZLF1 promoters were observed in ZVR-negative MCF-7 cells. ZVR failed to bind any of the previously identified negative regulatory elements within the BZLF1 promoter. We conclude that ZV functions as an important regulatory element of the BZLF1 promoter, with ZVR likely playing important roles in the maintenance of latency and reactivation of EBV.

Citing Articles

Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.

Kraus R, Cordes B, Sathiamoorthi S, Patel P, Yuan X, Iempridee T J Virol. 2020; 94(18).

PMID: 32641480 PMC: 7459560. DOI: 10.1128/JVI.00722-20.


Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma.

Halec G, Waterboer T, Brenner N, Butt J, Hardy W, DSouza G J Acquir Immune Defic Syndr. 2018; 80(3):e53-e63.

PMID: 30531297 PMC: 6375787. DOI: 10.1097/QAI.0000000000001916.


Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.

Reusch J, Nawandar D, Wright K, Kenney S, Mertz J J Virol. 2014; 89(3):1731-43.

PMID: 25410866 PMC: 4300755. DOI: 10.1128/JVI.02781-14.


Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Gorres K, Daigle D, Mohanram S, Miller G J Virol. 2014; 88(14):8028-44.

PMID: 24807711 PMC: 4097796. DOI: 10.1128/JVI.00722-14.


The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation.

Hawkins J, Delgado-Eckert E, Thorley-Lawson D, Shapiro M PLoS Pathog. 2013; 9(10):e1003685.

PMID: 24146621 PMC: 3798424. DOI: 10.1371/journal.ppat.1003685.


References
1.
Niederman J, Evans A, Subrahmanyan L, McCOLLUM R . Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med. 1970; 282(7):361-5. DOI: 10.1056/NEJM197002122820704. View

2.
Good P, Welch R, Ryu W, Mertz J . The late spliced 19S and 16S RNAs of simian virus 40 can be synthesized from a common pool of transcripts. J Virol. 1988; 62(2):563-71. PMC: 250569. DOI: 10.1128/JVI.62.2.563-571.1988. View

3.
Tovey M, Lenoir G . Activation of latent Epstein-Barr virus by antibody to human IgM. Nature. 1978; 276(5685):270-2. DOI: 10.1038/276270a0. View

4.
Luka J, Kallin B, Klein G . Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology. 1979; 94(1):228-31. DOI: 10.1016/0042-6822(79)90455-0. View

5.
Kallin B, Luka J, Klein G . Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol. 1979; 32(3):710-6. PMC: 525917. DOI: 10.1128/JVI.32.3.710-716.1979. View